# Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

> **NCT00492388** · PHASE3 · TERMINATED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 2 (actual)

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** PMI-150 (intranasal ketamine)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00492388
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Business decision not to continue development
- **Last updated:** 2012-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492388, "Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00492388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*